LACTOLOGY FOUNDATION

Almagate (A02AD03) – Toxicology and Breastfeeding Safety

Overview

Almagate (ATC class A02AD03) is a non‑systemic antacid composed of aluminum and magnesium hydroxide complexes used for symptomatic treatment of hyperacidity, heartburn, and other acid‑related dyspeptic complaints. It belongs to the group of combined aluminum–magnesium antacids, which exert their effect by neutralizing gastric hydrochloric acid and increasing intragastric pH without significant systemic absorption in individuals with normal renal function.

Pharmacology and mechanism

Almagate acts locally in the gastric lumen, neutralizing acid and increasing pH through the reaction of aluminum and magnesium hydroxide moieties with hydrochloric acid, forming insoluble salts and water. The onset of action is usually rapid, with symptomatic relief of heartburn and epigastric pain within minutes, and its effect is comparable to other aluminum‑magnesium antacid combinations.

The aluminum component also has a mild cytoprotective effect on the gastric mucosa, while the magnesium component may accelerate gastric emptying and counteract aluminum‑induced constipation. Because of poor gastrointestinal absorption of both ions from these complexes, systemic exposure is generally low, although it may increase in patients with renal impairment or in the setting of prolonged high‑dose use.

Toxicology profile

Acute toxicity of almagate is low, and serious toxic reactions are uncommon when used short term at recommended doses. The main toxicological concern arises from chronic exposure to aluminum and magnesium, particularly in patients with reduced kidney function or in those receiving long‑term, high‑dose antacid therapy.

Prolonged aluminum exposure can lead to hypophosphatemia through formation of insoluble aluminum–phosphate complexes, resulting in decreased phosphate absorption, osteomalacia, and muscle weakness. Accumulation of aluminum has been associated with neurological toxicity and dialysis encephalopathy in patients with severe renal failure. Excess magnesium exposure may cause hypermagnesemia, manifested by nausea, hypotension, neuromuscular depression, and, in severe cases, cardiac conduction disturbances, again mainly in the context of renal insufficiency or massive dosing.

Use in pregnancy

Available data suggest that non‑systemic aluminum–magnesium antacids, including preparations comparable to almagate, are acceptable for short‑term use in otherwise healthy pregnant women when clearly indicated. Pharmacokinetic studies in healthy volunteers have shown no measurable systemic absorption of aluminum from such antacid formulations and only normal serum magnesium concentrations, supporting a favorable safety profile during pregnancy.

Nevertheless, aluminum can cross the placenta, and the theoretical risk of accumulation in fetal tissues warrants avoidance of prolonged high‑dose or continuous use, especially in women with impaired renal function. For symptomatic management of gastroesophageal reflux or dyspepsia in pregnancy, short courses at the lowest effective dose are preferred, and calcium‑based antacids may be considered as alternatives in women at higher risk of aluminum load.

Excretion into breast milk

Both aluminum and magnesium from non‑systemic antacids exhibit minimal transfer into breast milk, and neither substance concentrates in milk to clinically relevant levels in healthy women. Measured aluminum concentrations in human milk are low, and reported data have not demonstrated adverse effects in breastfed infants associated specifically with maternal use of almagate or similar aluminum–magnesium antacids.

Because of the low oral bioavailability of these ions, the fraction ingested by the breastfed infant that reaches the systemic circulation is expected to be very small, except possibly in premature or very young neonates with increased intestinal permeability. International expert sources classify almagate and related aluminum–magnesium antacids as compatible or mostly safe during breastfeeding, provided use is intermittent and not excessive.

Lactation risk assessment

Non‑systemic antacids containing aluminum and magnesium, such as almagate, are generally considered low‑risk during lactation when used at standard doses for short periods. Chronic or high‑dose use should be avoided to limit cumulative aluminum exposure and because safer long‑term strategies (lifestyle measures, proton pump inhibitors with better lactation data) may be available for persistent acid‑related disorders.

Special caution is advisable in mothers of premature infants or newborns with renal impairment, where even small additional aluminum or magnesium loads may be less well tolerated. In such high‑risk situations, clinicians may prefer antacids with less aluminum content or alternative therapies with more extensive lactation safety data, while monitoring the infant for gastrointestinal intolerance, changes in feeding pattern, or unexplained lethargy.

Clinical use and indications

Almagate is indicated for symptomatic relief of hyperacidity, heartburn, sour stomach, and dyspeptic discomfort associated with acid‑related disorders. It may also be used as adjunctive therapy in conditions such as functional dyspepsia or non‑erosive gastroesophageal reflux disease where rapid local neutralization of acid is desired.

The drug is usually administered orally as a suspension, chewable tablet, or gel, taken between meals and at bedtime for optimal acid neutralization. Because it can interfere with the absorption of concomitant oral medications by binding in the gastrointestinal tract or altering gastric pH, a dosing interval (usually at least two hours) between almagate and other oral drugs is recommended.

Contraindications and precautions

Almagate and related aluminum–magnesium antacids are contraindicated in patients with known hypersensitivity to any component of the formulation. They should be used with particular caution, or avoided, in patients with severe renal impairment due to the increased risk of aluminum accumulation, hypermagnesemia, and profound hypophosphatemia.

Prolonged continuous use is not advisable without medical supervision, as persistent symptoms may indicate peptic ulcer disease, malignancy, or other serious gastrointestinal pathology that requires etiological diagnosis and targeted treatment. Patients on magnesium‑ or sodium‑restricted diets, or those taking multiple interacting medications (such as tetracyclines, quinolones, or oral iron), require individual risk–benefit assessment and adjustment of dosing intervals.

Adverse effects

At recommended doses, adverse effects are usually mild and transient, most commonly involving the gastrointestinal tract. Aluminum moieties may cause constipation, whereas magnesium tends to produce a laxative effect; the combination in almagate is designed to balance these opposing actions, but some patients still experience changes in stool consistency.

With prolonged or high‑dose therapy, more serious toxicities can occur, including hypophosphatemia with bone demineralization, aluminum intoxication with osteomalacia or neurological symptoms, and hypermagnesemia with neuromuscular and cardiovascular manifestations, especially in patients with compromised renal function. Rare systemic reactions such as dizziness, confusion, or respiratory depression have been reported with excessive use of aluminum–magnesium antacids and should prompt immediate discontinuation and clinical evaluation.

Practical recommendations for lactating patients

For otherwise healthy breastfeeding women with occasional heartburn or dyspepsia, short‑term, on‑demand use of almagate at the lowest effective dose is compatible with continued breastfeeding. Chronic daily use over extended periods should be avoided if possible, and if ongoing therapy is needed, clinicians should reassess the indication and consider alternatives with robust lactation safety data.

Mothers of premature or medically fragile infants should consult their healthcare provider before using aluminum‑containing antacids, and may benefit from individualized counseling on non‑pharmacological measures and alternative medications. As with all pharmacotherapy during lactation, monitoring of the infant’s feeding behavior, weight gain, and general well‑being is advisable, although clinically significant adverse effects from maternal almagate use are unlikely based on current evidence.